Bioenvision Inc. (NasdaqGM:BIVN) will hold a live webcast of its
quarterly conference call at 10:00a.m. EST on Thursday, February 8th,
2007. Jim Scibetta, Chief Financial Officer, will host the call.
Senior management will discuss the Company's financial results as of
December 31, 2006, the progress towards its goals, and additional
corporate activities, including the EMeA filing for Evoltra(R) in
adult acute myeloid leukemia (AML). Bioenvision will announce the
highlights of these topics in a press release to be issued before the
market opens on February 8, 2007, prior to the conference call.
-0-
*T
Conference Call Information:
Date: 2/8/07
Time: 10:00a.m. Eastern Standard Time
Toll free (US & Canada): 866-585-6398
International: 416-849-9626
Webcast: www.bioenvision.com
A replay of the call and webcast will be available for 14 days.
Replay number (US & Canada): 866-245-6755
Replay number international: 416-915-1035
Replay passcode: 752762
Webcast replay: www.bioenvision.com
*T
About Bioenvision
Bioenvision's primary focus is the acquisition, development and
marketing of compounds and technologies for the treatment of cancer.
Bioenvision has a broad pipeline of products for the treatment of
cancer, including: Evoltra(R), Modrenal(R) (for which Bioenvision has
obtained regulatory approval for marketing in the United Kingdom for
the treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products. Bioenvision is also
developing anti-infective technologies, including the OLIGON(R)
technology; an advanced biomaterial that has been incorporated into
various FDA approved medical devices and Suvus(R), an antimicrobial
agent currently in clinical development for refractory chronic
hepatitis C infection. For more information on Bioenvision please
visit our Web site at www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.
